rss
J Clin Pathol doi:10.1136/jcp.2007.052225

Characteristics of KIT-negative gastrointestinal stromal tumors and diagnostic utility of protein kinase C theta immunostaining

  1. Hee Eun Lee (ichcream{at}empal.com)
  1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of
    1. Min A Kim (kmamd{at}hanmail.net)
    1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of
      1. Hye Seung Lee (mw9195{at}hanmail.net)
      1. Department of Pathology, Seoul National University Bundang Hospital, Korea, Republic of
        1. Byung Lan Lee (dslanat{at}snu.ac.kr)
        1. Cancer Research Institute, Seoul National University College of Medicine, Korea, Republic of
          1. Woo Ho Kim (array123{at}freechal.com)
          1. Department of Pathology, Seoul National University College of Medicine, Korea, Republic of
            • Published Online First 1 April 2008

            Abstract

            AIMS: The present study aimed to characterise KIT-negative gastrointestinal stromal tumor (GIST) clinically, pathologically, immunohistochemically, and genetically and to establish the usefulness of protein kinase C theta (PKCθ as a diagnostic marker in KIT-negative GIST.

            METHODS: A total of 252 consecutive cases of GIST were evaluated for clinicopathologic characteristics and immunostained for various antibodies. The mutational analyses of KIT and platelet-derived growth factor receptor α (PDGFRA) were also performed in 62 cases.

            RESULTS: Twenty (7.9%) GISTs showed negative immunostaining for KIT. KIT-negative GISTs were more likely to originate from omentum or peritoneum, have an epithelioid histology, and be classified as high risk. The overall survival rate of patients with KIT-negative GISTs (five-year survival rate, 68.7 ±10.7%) was lower than that of patients with KIT-positive GISTs (five-year survival rate, 79.9 ±3.0%) (P = 0.042, log-rank test), and it was found that negative KIT expression was an independent prognostic factor in multivariate Cox regression analysis when the risk of aggressive behavior and the status of imatinib treatment were adopted as covariates. KIT-negative GISTs also showed lower expression rates of CD34, Bcl-2, and PKCθ than KIT-positive GISTs, and mutational analysis revealed that 30% of KIT-negative GISTs harbored a PDGFRA exon 18 mutation. Immunostaining on PKCθ showed that 93.9% of all GISTs expressed PKCθ protein. However, 21.9% of 64 mesenchymal tumors other than GIST also showed positivity on PKCθ

            CONCLUSIONS: KIT-negative GISTs had characteristics that differ from those of KIT-positive GISTs, and negative KIT expression was an independent prognostic indicator for overall survival of patients. Although PKCθ is a sensitive diagnostic marker for GIST, its usefulness is limited because of low sensitivity and low specificity in KIT-negative GISTs.

            This Article

            1. All Versions of this Article:
              1. jcp.2007.052225v1
              2. 61/6/722 most recent

            Services

            1. Request permissions

            Responses

            1. Submit a response
            2. No responses published

            Social bookmarking

            Latest from JCP Education

            Latest from JCP Education

            Register for free content


            Free sample
            This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
            View free sample issue >>

            Free archive
            The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
            Register to access the free archive >>

            Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

          1. Latest Pathology jobs

            Latest Pathology jobs